Clinical Usefulness of HLA-B∗58:01 Genotyping in Gouty Arthritis

Abstract

Allopurinol is an effective urate lowering agent but may lead to rare but life-threatening severe cutaneous adverse reactions (SCAR). Genetic predisposition, age, sex, renal function, dosage and concomitant diuretic use are known risk factors of allopurinol related SCAR. Among these factors, HLA-B∗58:01 confers the highest risk. Frequency of the HLA-B∗58:01 allele varies significantly across different ethnic groups. Although the usefulness of HLA-5801 genotyping before initiation of allopurinol has been confirmed by clinical studies, its positive predictive value for SCAR is low because of the low prevalence of HLA-5801 in some localities. Thus, health economic analysis does not consistently show cost-effectiveness of universal screening of HLA-5801 before initiation of allopurinol. However, screening of this genotype in high-risk subjects, including those with renal impairment or advanced age, should be considered on individual basis.

Keywords

• hla-b∗58:01
• allopurinol
• hypersensitivity
• severe cutaneous adverse reactions
• cost-effectiveness
• genetic screening